Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma

RAD51D is a key player in DNA repair by homologous recombination (HR), and truncating variant carriers have an increased risk for ovarian cancer. However, the contribution of nontruncating variants to cancer predisposition remains uncertain. Using deep sequencing and case-control genotyping studies,...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2017-08, Vol.77 (16), p.4517-4529
Main Authors: Rivera, Barbara, Di Iorio, Massimo, Frankum, Jessica, Nadaf, Javad, Fahiminiya, Somayyeh, Arcand, Suzanna L, Burk, David L, Grapton, Damien, Tomiak, Eva, Hastings, Valerie, Hamel, Nancy, Wagener, Rabea, Aleynikova, Olga, Giroux, Sylvie, Hamdan, Fadi F, Dionne-Laporte, Alexandre, Zogopoulos, George, Rousseau, Francois, Berghuis, Albert M, Provencher, Diane, Rouleau, Guy A, Michaud, Jacques L, Mes-Masson, Anne-Marie, Majewski, Jacek, Bens, Susanne, Siebert, Reiner, Narod, Steven A, Akbari, Mohammad R, Lord, Christopher J, Tonin, Patricia N, Orthwein, Alexandre, Foulkes, William D
Format: Article
Language:English
Subjects:
Adult
Aged
Case depth
Case-Control Studies
DNA repair
DNA-Binding Proteins - genetics
Endometrium
Female
Genotype
Genotyping
Health risks
Homologous recombination
Homology
Humans
Middle Aged
Missense mutation
Mutation
Mutation, Missense
Ovarian cancer
Ovarian carcinoma
Ovarian Neoplasms - genetics
Ovarian Neoplasms - pathology
Pancreas
Pedigree
Poly(ADP-ribose) polymerase
Polymorphism, Single Nucleotide
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:RAD51D is a key player in DNA repair by homologous recombination (HR), and truncating variant carriers have an increased risk for ovarian cancer. However, the contribution of nontruncating variants to cancer predisposition remains uncertain. Using deep sequencing and case-control genotyping studies, we show that in French Canadians, the missense variant c.620C>T;p.S207L is highly prevalent and is associated with a significantly increased risk for ovarian high-grade serous carcinoma (HGSC; 3.8% cases vs. 0.2% controls). The frequency of the p.S207L variant did not significantly differ from that of controls in breast, endometrial, pancreas, or colorectal adenocarcinomas. Functionally, we show that this mutation impairs HR by disrupting the RAD51D-XRCC2 interaction and confers PARP inhibitor sensitivity. These results highlight the importance of a functional RAD51D-XRCC2 interaction to promote HR and prevent the development of HGSC. This study identifies c.620C>T;p.S207L as the first bona fide pathogenic missense cancer susceptibility allele and supports the use of targeted PARP-inhibitor therapies in ovarian cancer patients carrying deleterious missense variants. .
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-17-0190